Ontrak, Inc. (OTRK) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Core Viewpoint - First Commonwealth Financial (FCF) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - For the fiscal year ending December 2025, First Commonwealth Financial is expected to earn $1.45 per share, with a 3.8% increase in the Zacks Consensus Estimate over the past three months [9]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which in turn affects stock prices [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of First Commonwealth Financial to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are ...

Group 1: Southwest Airlines Performance - Southwest Airlines (LUV) shares increased by 8.1% to close at $37.35, with trading volume significantly higher than usual [1] - The stock's performance is in contrast to a 3.1% gain over the past four weeks [1] Group 2: Industry Context - The positive movement in Southwest's stock is attributed to optimism in the airline industry following Delta Air Lines' better-than-expected second-quarter 2025 earnings results [2] - Delta's earnings and revenue exceeded expectations, and the restoration of full-year guidance has pleased investors [2] Group 3: Earnings Estimates and Trends - Southwest's consensus EPS estimate for the upcoming quarter has been revised down by 20.3% over the last 30 days [4] - A negative trend in earnings estimate revisions typically does not lead to price appreciation, indicating potential caution for future stock performance [4] Group 4: Comparison with JetBlue Airways - JetBlue Airways (JBLU) also saw a stock increase of 7.8% to close at $4.56, but has returned -13% over the past month [5] - JetBlue's consensus EPS estimate has changed by -85% over the past month to -$0.31, reflecting a significant decline from the previous year [6]

A downtrend has been apparent in Ontrak, Inc. (OTRK) lately. While the stock has lost 12.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the ...

Group 1 - Greenbrier Companies (GBX) has recently reached a key level of support and has overtaken the 200-day moving average, indicating a long-term bullish trend [1] - GBX shares have increased by 20% over the past four weeks, and the company holds a Zacks Rank 2 (Buy), suggesting potential for continued growth [2] - Positive earnings estimate revisions for GBX further strengthen the bullish outlook, with no estimates decreasing in the past two months and one estimate increasing [3] Group 2 - The 200-day simple moving average is a useful tool for determining long-term market trends and serves as a support or resistance level [2] - The combination of positive earnings estimate revisions and technical indicators positions GBX as a stock to watch for potential gains [3]

Core Viewpoint - Analysts project that Bank of America (BAC) will report quarterly earnings of $0.86 per share, a 3.6% increase year over year, with revenues expected to reach $26.61 billion, up 4.9% from the same quarter last year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised upward by 0.8%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Forecast - The 'Efficiency Ratio (FTE basis)' is expected to reach 64.5%, compared to 63.9% in the same quarter last year [5]. - The 'Book value per share of common stock' is projected at $36.85, up from $34.39 a year ago [5]. - 'Total earning assets - Average balance' is forecasted to be $2975.40 billion, compared to $2887.94 billion in the same quarter last year [6]. - 'Total nonperforming loans, leases and foreclosed properties' are expected to be $6.66 billion, up from $5.69 billion a year ago [6]. - The estimated 'Total Non-Performing Loans' is $6.62 billion, compared to $5.47 billion in the same quarter last year [7]. - The 'Tier 1 Capital Ratio' is projected at 13.0%, down from 13.5% a year ago [7]. - The 'Net Interest Income - Fully taxable-equivalent basis' is expected to reach $14.88 billion, compared to $13.86 billion last year [8]. - 'Total Noninterest Income' is projected at $11.80 billion, slightly up from $11.68 billion in the same quarter last year [8]. - 'Investment and brokerage services' are expected to reach $4.73 billion, compared to $4.32 billion a year ago [9]. - The consensus estimate for 'Investment banking fees' stands at $1.34 billion, down from $1.56 billion in the same quarter last year [9]. - 'Total fees and commissions' are expected to be $9.29 billion, compared to $8.97 billion last year [9]. Stock Performance - Shares of Bank of America have increased by 5.3% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.1% [10].

Core Viewpoint - Johnson & Johnson (JNJ) is expected to report quarterly earnings of $2.66 per share, reflecting a 5.7% decline year-over-year, while revenues are forecasted to increase by 1.5% to $22.79 billion [1] Earnings Estimates - The consensus EPS estimate has been revised 0.5% higher in the last 30 days, indicating analysts' positive reassessment of the company's performance [1][2] Revenue Estimates by Segment - **MedTech Total Sales**: Estimated at $8.25 billion, indicating a year-over-year increase of 3.7% [3] - **Innovative Medicine Worldwide Sales**: Expected to reach $14.55 billion, reflecting a 0.4% increase from the prior year [4] - **Innovative Medicine Immunology Sales**: Forecasted at $3.86 billion, showing an 18.2% decline year-over-year [4] - **Innovative Medicine Neuroscience Sales**: Anticipated to be $1.99 billion, representing an 11.6% increase [4] Specific Product Sales Estimates - **Oncology CARVYKTI Sales**: Projected at $409.72 million, indicating a significant increase of 120.3% from the previous year [5] - **Neuroscience SPRAVATO Sales**: Expected to be $371.85 million, reflecting a 37.2% increase [5] - **MedTech Cardiovascular ABIOMED Sales**: Estimated at $423.95 million, showing an 11.9% increase [6] - **MedTech Orthopaedics Hips US Sales**: Projected at $269.05 million, indicating a 1.5% increase [7] Organic Sales Growth - Analysts predict an organic sales growth of 2.7%, down from 6.6% reported in the same quarter last year [8] Stock Performance - Johnson & Johnson shares have increased by 0.7% over the past month, compared to a 4.1% increase in the Zacks S&P 500 composite [8]

Emerson Electric (EMR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this maker of process controls systems, valves and analytical instruments have returned +11% over the past month versus the Zacks S&P 500 composite's +4.1% change. The Zacks Manufacturing - Electronics industry, to which Emerson Electric belongs, has gained 10% over this period. Now th ...

Company Overview - Seanergy Maritime Holdings Corp (SHIP) shares increased by 6.8% to close at $6.76, following notable trading volume compared to typical sessions, despite a 7.3% loss over the past four weeks [1] - The stock has gained 7% in the current month, supported by the stabilization of the Baltic Exchange's dry bulk sea freight index, with improvements in the Panamax and Supramax segments offsetting declines in Capesize rates [2] Financial Performance - The company is expected to report quarterly earnings of $0.09 per share, reflecting a year-over-year decline of 88.3%, with revenues projected at $35.13 million, down 18.5% from the same quarter last year [3] - Management remains optimistic about the Capesize market for the remainder of 2025, which could positively impact the company's future performance [3] Market Sentiment - The consensus EPS estimate for Seanergy Maritime has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [5] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [6]